Page last updated: 2024-08-18

pyrroles and baricitinib

pyrroles has been researched along with baricitinib in 46 studies

Research

Studies (46)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	31 (67.39)	24.3611
2020's	15 (32.61)	2.80

Authors

Authors	Studies
Warren, RB; Yiu, ZZ	1
Iwata, S; Tanaka, Y	1
Tanaka, Y	1
Iwata, S; Kubo, S; Nakayamada, S; Tanaka, Y	1
Ahmad Nasrollahi, S; Firooz, A; Hashemi, A; Nassiri Kashani, M; Samadi, A	1
Damsky, W; King, BA	1
Ramot, Y; Shreberk-Hassidim, R; Zlotogorski, A	1
Winthrop, KL	1
Bijlsma, J; Burmester, G; Chatzidionysiou, K; Dougados, M; Emamikia, S; Landewé, R; Nam, J; Ramiro, S; Scholte, M; Smolen, J; van der Heijde, D; van Vollenhoven, R	1
Mitchell, TS; Moots, RJ; Wright, HL	1
Deleuran, B; Eggertsen, PP; Frøling, M; Mikkelsen, C; Stern, M; van de Looij, A	1
Cardwell, LA; Cline, A; Feldman, SR	1
Hider, SL; Scott, DL; Scott, IC	1
Kotyla, PJ	1
Atzeni, F; Gerratana, E; Marino, F; Masala, IF; Nucera, V; Sangari, D; Sarzi-Puttini, P; Talotta, R	1
Bae, SC; Lee, YH	1
Choy, EH	2
Castañeda, S; Morell Baladrón, A; Serra López-Matencio, JM	1
Westhovens, R	1
Taylor, PC	1
Santos, LDN; Shapiro, J	1
Atzeni, F; Bechman, K; Cope, AP; Galli, M; Galloway, JB; Norton, S; Subesinghe, S; Winthrop, KL	1
Aykara, I; Diller, M; Frommer, K; Hasseli, R; Hülser, ML; Müller-Ladner, U; Neumann, E; Rehart, S	1
Witte, T	1
Kwon, O; Park, H; Yu, DA	1
Bonelli, M; Dalwigk, K; Hayer, S; Holinka, J; Karonitsch, T; Kiener, HP; Niederreiter, B; Olmos Calvo, I; Pap, T; Platzer, A; Sevelda, F; Smolen, JS; Steiner, G; Superti-Furga, G	1
Byers, NL; Higgs, RE; Lee, J; Macias, WL; McInnes, IB; Na, S; Ortmann, RA; Rocha, G; Rooney, TP; Taylor, PC; Wehrman, T; Zhang, X; Zuckerman, SH	1
Krüger, K	1
Dowty, ME; Hegen, M; Jesson, MI; Katkade, V; Lin, TH; Martin, DA; Menon, S; Telliez, JB	1
Bonovas, S; Danese, S; Lasa, JS; Olivera, PA; Peyrin-Biroulet, L	1
Lee, YH; Song, GG	2
Caso, F; Chimenti, MS; Costa, L; Del Puente, A; Giacomelli, R; Girolimetto, N; Navarini, L; Ruscitti, P; Scarpa, R	1
Georgiou, S; Plachouri, KM	1
Damsky, W; King, B; Peterson, D	1
Betts, KA; Du, EX; Pope, J; Qi, CZ; Sawant, R; Song, Y; Tang, P; Tundia, N	1
Bajocchi, G; Beltrami, M; Boiardi, L; Cassone, G; Catanoso, M; Cimino, L; Costantini, M; Croci, S; Di Lernia, V; Dolci, G; Galli, E; Giorgi Rossi, P; Girolimetto, N; Gradellini, F; Mancuso, P; Marata, AM; Massari, M; Muratore, F; Pipitone, N; Salvarani, C	1
Morinobu, A	1
Amuro, H; Ebina, K; Hara, R; Hashimoto, M; Hirano, T; Hirao, M; Jinno, S; Katayama, M; Kumanogoh, A; Maeda, Y; Murata, K; Nakata, K; Okita, Y; Onishi, A; Son, Y; Takeuchi, T; Yamamoto, K; Yamamoto, W; Yoshikawa, A	1
Gong, Y; Qi, F; Zhang, J; Zhou, S; Zhu, B	1
Aramaki, T; Eguchi, K; Endo, Y; Fujikawa, K; Ichinose, K; Igawa, T; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Kurushima, S; Michitsuji, T; Mizokami, A; Nakamura, H; Nishihata, S; Okada, A; Okamoto, M; Origuchi, T; Sato, S; Shimizu, T; Sumiyoshi, R; Suzuki, T; Tamai, M; Tsuji, Y; Ueki, Y	1
Askling, J; Barbulescu, A; Chatzidionysiou, K; Forsblad-d'Elia, H; Frisell, T; Kastbom, A; Lindström, U; Turesson, C	1
Cañada Martínez, AJ; Fragío Gil, JJ; González Mazarío, R; González Puig, L; Grau García, E; Ivorra Cortés, J; Negueroles Albuixech, RM; Román Ivorra, JA	1
Bertolini, N; Caso, F; Costa, L; Del Puente, A; Luppino, JME; Mostacciuolo, E; Passavanti, S; Peluso, R; Santelli, F; Scarpa, R; Tasso, M	1

Reviews

33 review(s) available for pyrroles and baricitinib

Article	Year
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis. American journal of clinical dermatology, 2016, Volume: 17, Issue:3 Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles	2016
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert review of clinical immunology, 2016, Volume: 12, Issue:10 Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Heterocyclic Compounds, 2-Ring; Humans; Janus Kinase 1; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Valine	2016
[Tofacitinib for the treatment of rheumatoid arthritis]. Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74, Issue:6 Topics: Administration, Ophthalmic; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Drug Discovery; Humans; Janus Kinases; Lymphocytes; Molecular Targeted Therapy; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides; Treatment Outcome	2016
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2016, Volume: 30, Issue:5 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles	2016
Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. The Journal of dermatological treatment, 2017, Volume: 28, Issue:6 Topics: Alopecia Areata; Azetidines; Dermatitis, Atopic; Humans; Janus Kinase Inhibitors; Janus Kinases; Nitriles; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Skin Diseases; Sulfonamides; Vitiligo	2017
JAK inhibitors in dermatology: The promise of a new drug class. Journal of the American Academy of Dermatology, 2017, Volume: 76, Issue:4 Topics: Alopecia Areata; Anti-Inflammatory Agents; Azetidines; Clinical Trials as Topic; Dermatitis, Atopic; Dermatologic Agents; Humans; Janus Kinases; Molecular Targeted Therapy; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Skin Diseases; Sulfonamides; Vitiligo	2017
Janus kinase inhibitors in dermatology: A systematic review. Journal of the American Academy of Dermatology, 2017, Volume: 76, Issue:4 Topics: Alopecia Areata; Anti-Inflammatory Agents; Antineoplastic Agents; Azetidines; Dermatologic Agents; Drug Eruptions; Humans; Janus Kinases; Molecular Targeted Therapy; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Skin Diseases; Sulfonamides	2017
The emerging safety profile of JAK inhibitors in rheumatic disease. Nature reviews. Rheumatology, 2017, Volume: 13, Issue:4 Topics: Azetidines; Humans; Infections; Janus Kinases; Neoplasms; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rheumatic Diseases; Signal Transduction; Sulfonamides	2017
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases, 2017, Volume: 76, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Glucocorticoids; Humans; Methotrexate; Piperidines; Practice Guidelines as Topic; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides	2017
Two new drugs for rheumatoid arthritis. Drug and therapeutics bulletin, 2017, Volume: 55, Issue:9 Topics: Arthritis, Rheumatoid; Azetidines; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2017
[Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis]. Ugeskrift for laeger, 2017, Oct-30, Volume: 179, Issue:44 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Humans; Janus Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2017
Advances in treating psoriasis in the elderly with small molecule inhibitors. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:18 Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide	2017
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? Drug safety, 2018, Volume: 41, Issue:7 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Humans; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Thromboembolism	2018
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients? BioMed research international, 2018, Volume: 2018 Topics: Animals; Azetidines; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rheumatic Fever; Sulfonamides	2018
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert review of clinical immunology, 2018, Volume: 14, Issue:11 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Humans; Janus Kinase 1; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2018
Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Zeitschrift fur Rheumatologie, 2019, Volume: 78, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Humans; Network Meta-Analysis; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides	2019
Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford, England), 2019, 06-01, Volume: 58, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Humans; Inflammation; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2019
JAK-STAT inhibitors for the treatment of immunomediated diseases. Medicina clinica, 2019, 05-03, Volume: 152, Issue:9 Topics: Autoimmune Diseases; Azetidines; Humans; Immunologic Factors; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; STAT Transcription Factors; Sulfonamides	2019
Clinical efficacy of new JAK inhibitors under development. Just more of the same? Rheumatology (Oxford, England), 2019, 02-01, Volume: 58, Issue:Suppl 1 Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine	2019
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford, England), 2019, 02-01, Volume: 58, Issue:Suppl 1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome	2019
What's New in Hair Loss. Dermatologic clinics, 2019, Volume: 37, Issue:2 Topics: 5-alpha Reductase Inhibitors; Alopecia; Alopecia Areata; Azetidines; Humans; Janus Kinase Inhibitors; Nitriles; Piperidines; Platelet-Rich Plasma; Purines; Pyrazoles; Pyrimidines; Pyrroles; Retinoids; Sulfonamides	2019
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford, England), 2019, 10-01, Volume: 58, Issue:10 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Infections; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides	2019
[JAK Inhibitors in Rheumatology]. Deutsche medizinische Wochenschrift (1946), 2019, Volume: 144, Issue:11 Topics: Arthritis, Rheumatoid; Azetidines; Germany; Humans; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2019
Janus kinase inhibitors: An innovative treatment for alopecia areata. The Journal of dermatology, 2019, Volume: 46, Issue:8 Topics: Administration, Oral; Alopecia Areata; Azetidines; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Janus Kinase Inhibitors; Janus Kinases; Middle Aged; Nitriles; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides; T-Lymphocytes, Cytotoxic; Treatment Outcome	2019
[Role of janus kinase inhibitors in the treatment of rheumatic diseases]. Der Internist, 2019, Volume: 60, Issue:11 Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome	2019
Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatology (Oxford, England), 2019, 11-01, Volume: 58, Issue:Suppl 5 Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Fatigue; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2019
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, Volume: 158, Issue:6 Topics: Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Placebos; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfonamides; Survival Analysis; Treatment Outcome; Triazoles	2020
Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:7 Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Psoriatic; Azetidines; Humans; Janus Kinases; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Thalidomide; Treatment Outcome	2020
JAK inhibitors in chronic plaque psoriasis: What is known so far. Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:2 Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles	2020
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Advances in therapy, 2020, Volume: 37, Issue:5 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Methotrexate; Network Meta-Analysis; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides	2020
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. Zeitschrift fur Rheumatologie, 2021, Volume: 80, Issue:4 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles	2021
JAK inhibitors for the treatment of rheumatoid arthritis. Immunological medicine, 2020, Volume: 43, Issue:4 Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism	2020
Biological Therapies for Atopic Dermatitis: A Systematic Review. Dermatology (Basel, Switzerland), 2021, Volume: 237, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azetidines; Biological Products; Carbamates; Clinical Trials as Topic; Dermatitis, Atopic; Dermatologic Agents; Heterocyclic Compounds, 3-Ring; Humans; Nitriles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2021

Other Studies

13 other study(ies) available for pyrroles and baricitinib

Article	Year
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production. Clinical and experimental immunology, 2017, Volume: 189, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Azetidines; Case-Control Studies; Cell Movement; Cells, Cultured; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-8; Janus Kinases; Male; Middle Aged; Neutrophils; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Reactive Oxygen Species; Respiratory Burst; Sulfonamides; Tetradecanoylphorbol Acetate; United Kingdom	2017
Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib. Frontiers in immunology, 2019, Volume: 10 Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Cell Proliferation; Chemokine CCL2; Fibroblasts; Humans; Interleukin-6; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Synovial Membrane	2019
IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSs. Experimental & molecular medicine, 2019, 07-08, Volume: 51, Issue:7 Topics: Animals; Arthritis, Rheumatoid; Azetidines; Biomarkers; Female; Gene Expression; Humans; Inflammation; Interferon Regulatory Factor-1; Interferons; Janus Kinase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Transgenic; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides; Synovial Membrane; Synoviocytes; Tumor Necrosis Factor-alpha	2019
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis research & therapy, 2019, 08-02, Volume: 21, Issue:1 Topics: Arthritis, Rheumatoid; Azetidines; Biomarkers; Cytokines; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Leukocytes, Mononuclear; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides	2019
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacology research & perspectives, 2019, Volume: 7, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cell Line; Cytokines; Enzyme Assays; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Janus Kinase 1; Janus Kinase Inhibitors; Male; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Cytokine; Sulfonamides; Triazoles	2019
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Zeitschrift fur Rheumatologie, 2020, Volume: 79, Issue:8 Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles	2020
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Journal of the American Academy of Dermatology, 2020, Volume: 82, Issue:6 Topics: Arthritis, Rheumatoid; Azetidines; Betacoronavirus; Colitis, Ulcerative; Coronavirus Infections; COVID-19; Cytokines; Dermatitis, Atopic; Heterocyclic Compounds, 3-Ring; Humans; Immunomodulation; Janus Kinases; Nitriles; Pandemics; Piperidines; Pneumonia, Viral; Primary Myelofibrosis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; SARS-CoV-2; STAT Transcription Factors; Sulfonamides	2020
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Annals of the rheumatic diseases, 2020, Volume: 79, Issue:7 Topics: Abatacept; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Susceptibility; Female; Hospitalization; Humans; Interleukin 1 Receptor Antagonist Protein; Italy; Janus Kinase Inhibitors; Logistic Models; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Proportional Hazards Models; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rheumatic Diseases; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sulfonamides; Tumor Necrosis Factor Inhibitors; Ustekinumab	2020
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study. Clinical rheumatology, 2021, Volume: 40, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cohort Studies; Female; Humans; Methotrexate; Middle Aged; Pharmaceutical Preparations; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome	2021
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis. Arthritis research & therapy, 2021, 07-23, Volume: 23, Issue:1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome	2021
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology (Oxford, England), 2022, 10-06, Volume: 61, Issue:10 Topics: Abatacept; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Cohort Studies; Humans; Interleukin-6; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rituximab; Sulfonamides; Sweden; Treatment Outcome; Tumor Necrosis Factor Inhibitors	2022
Real-world Effectiveness and Safety of JAK Inhibitors in Rheumatoid Arthritis: A Single-centre Study. Reumatologia clinica, 2022, Volume: 18, Issue:9 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Humans; Janus Kinase Inhibitors; Pyrroles; Retrospective Studies	2022
Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy. Reumatismo, 2022, Dec-29, Volume: 74, Issue:3 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome	2022